In the present study, a progressive increase in HER2 immunoreactivity was observed, from the poorly cohesive histotype (3.5%) to MRCs (11.1%), tubular/papillary adenocarcinomas (31.3%) and HACs (42.9%). This evidence concerns the gene ERBB2 and papillary adenocarcinoma.